rewrite:Lasmiditan is a centrally penetrant, selective serotonin 1F receptor agonist (5-HT1F) and is the frst approved drug in the novel 'ditan' class of medications. Lasmiditan was approved in October 2019 in the United States for the acute treatment of migraines with or without aura in adults and is now available in many countries [6, 7]. In studies of single-migraine attacks (SAMURAI, SPARTAN, and MONONOFU), lasmiditan demonstrated statistically signifcant superiority versus placebo in the proportion of patients who were pain-free as well as the proportion of patients who were free of their migraine-associated most bothersome symptom at 2 h postdose [8-10]. Lasmiditan additionally demonstrated efcacy and consistency of response across multiple attacks